Conference Organizations, Presentations, Lectures and Seminars (2000-Present):

Conference Organizer, Section Chair/Moderator

1. Chair. Section "Drug Delivery", Pharmaceutical Science Symposium Celebrating Rutgers 250 Years", Piscataway, NJ, September 12-13, 2016.

2. Chair, Session “Nanomedicine”, 16^th International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, UT, February 5, 2013.

3. Chair, Organizing Committee, 10^th International Nanomedicine and Drug Delivery Symposium (NanoDDS’12), Atlantic City, NJ, December 5-7, 2012.

4. Member, Organizing Committee and Session Chair, 9^th International Nanomedicine and Drug Delivery Symposium (NanoDDS’11), Salt Lake City, UT, October 15-16, 2011.

5. Chair, Session “Oncology and Tumor targeting”, 38^th Annual Meeting of the Controlled Release Society, National Harbor, MD, August 2, 2011.

6. Program Chair, the 36th Annual Meeting of the Controlled Release Society, Copenhagen, Denmark (2008-2009).

7. Chair, Session “Inhaled Medicine”, the 36th Annual Meeting of the Controlled Release Society, Copenhagen, Denmark, July 22, 2009.

8. Section Chair, 2008 NSTI Nanotech 2008 11th Annual Meeting, NCI/NSTI Special Symposium on Nanotechnology for Cancer Prevention, Diagnosis and Treatment, Boston, MA, June 4, 2008.

9. Chair and Moderator, Section “Nanotechnology Approaches for Bioimaging”, the Fourth International Nanomedicine and Drug Delivery Symposium, Omaha, Nebraska, October 9, 2006.

10. Chair, Section “Drug Delivery Systems“, the 7th International Biorelated Polymers Symposium at the 232nd American Chemical Society Meeting, San Francisco, California, September 12, 2006.

11. Chair, Section “Biomimetic Carriers”, the 33^rd Annual Meeting of the Controlled Release Society, Vienna, Austria, July 23, 2006.

12. Conference Organizer and Chair, the Biennial New Jersey Pharmaceutical Conference of 2005 “Contribution of Women in the Pharmaceutical Sciences”, East Brunswick, NJ, October 6, 2005.

13. Chair and Moderator, Section “Targeted Delivery of Anticancer Agents”, the Third International Nanomedicine and Drug Delivery Symposium, Baltimore, Maryland, September 27, 2005.

14. Chair and Moderator, Section “Receptor Mediated Drug Targeting”, 31^st International Symposium on Controlled Release of Bioactive Materials, Honolulu. Hawaii, June 12, 2004.

15. Chair, Section “Pharmacology and Biochemistry”, 8^th World Congress on Advances in Oncology and 6^th International Symposium on Molecular Medicine, Hersonissos, Crete, Greece, October 16, 2003.

16. Chair, Section “Pharmacology and Biochemistry”, 7^th World Congress on Advances in Oncology and 5^th International Symposium on Molecular Medicine, Hersonissos, Crete, Greece, October 10, 2002.

17. Chair and Member of the Student Poster Session Committees for the following conferences:

· The Ninth International Nanomedicine and Drug Delivery Symposium, Salt Lake City, UT, October 15-16, 2011.

· Toward the Development of Drug Delivery Systems, 2^nd Annual Meeting of Italian Chapter of AAPS, Perugia, Italy, March 7, 2008.

· The Fifth International Nanomedicine and Drug Delivery Symposium, Boston, MA, November 2, 2007.

· GRASP 2007, 27th Annual Meeting, New Brunswick, NJ, June 1-3, 2007.

· Targeted Nanocarriers and Therapeutics, Institute for Translational Medicine and Therapeutics, The University of Pennsylvania School of Medicine, Philadelphia, PA, November 16, 2006.

Keynote/Plenary/Invited Lectures and Seminars

1. "Nanotechnology Approaches for Inhalation Treatment of Lung Deceases", Pharmaceutical Science Symposium Celebrating Rutgers 250 Years", Piscataway, NJ, Septmber 13, 2016.

2. "Nanotechnology Approaches for Inhalation Treatment of Lung Deceases", Oklahoma State University, May 18, 2016.

3. "Nanotechnology Approaches for Personalized and Targeted Treatment of Cancer", University of Missouri, Kansas City, MO, March 15, 2016.

4. "Nanotechnology Approaches for Personalized and Targeted Treatment of Cancer", AAPS Workshop on Nanotechnology in Personalized Medicine", Orlando, FL, October 25, 2015.

5. "Lipid-Based Microencapsulation for Drug and Gene Delivery in Lung Diseases", 20th International Symposium on Microencapsulation (IMS2015), October 3-5, 2015, Boston, MA.

6. "Advances in Nanomedicine Application for Therapy and Imaging", Evonik Meets Science, North America 2015 Innovations in Drug Delivery Technologies, September 14, 2015, Jersey City, NJ.

7. “Nanotechnology Approach for Inhalation Treatment of Lung Cancer”, Cancer Drug Discovery and Enabling Technologies Symposium, RCIPR, April 10, 2015, Piscataway, NJ.

8. “Nanotechnology Approaches for Personalized Treatment of Cancer”, 3rd Nanomedicine Conference, March 13-14, 2015, Los Angeles, CA.

9. “Tumor-Targeted Nanotherapeutics”, University of Pittsburgh, March 3, 2015, Pittsburgh, PA.

10. “Tumor-Targeted Nanotherapeutics”, Capital Region Cancer Research New Frontiers Symposium 2014: New Strategies and Technologies in Cancer Research, November 14, 2014, Albany, NY.

11. “Nanotechnology Approaches for Personalized Treatment of Cancer “, Targeted therapeutics and Translational Medicine 2014 Symposium, November 12, 2014, Philadelphia, PA.

12. “Drug delivery systems for lungs”, NHLBI Workshop: Precision Therapeutics Delivery for Lung Diseases: State of the Art Technologies and Lung Biology, September 24, 2014, Bethesda, MD.

13. “Tumor-Targeted Nanotherapeutics”, TechConnect World 2014 Congress, Cancer Nanotechnology II, June 16, 2014, Washington, D.C.

14. “Tumor-Targeted Nanotherapeutics”, School of Pharmacy, University of Connecticut, April 29, 2014, Storrs, CT.

15. “Nanotechnology-Based Method for Treatment of Primary Ovarian Cancer and Prevention of Metastases”, Molecular Response, April 4, 2014, San Diego, CA.

16. “Tumor-Targeted Nanotherapeutics”, 2013 Eastern Pharmaceutical Technology Meeting (EPTM), September 20, 2013, Basking Ridge, NJ.

17. “Targeted Drug Delivery of Chemotherapeutics Utilizing Nanoparticle and Liposomal Formulations”, 2013 Medicinal Chemistry Gordon Research Conference, August 6, 2013, New London, NH.

18. “Nanotechnology Strategies to Overcome Drug Resistance”, 2nd Nanomedicine for Imaging and Treatment Conference, Cedars-Sinai Medical Center, March 16, 2013, Los Angeles, CA.

19. “Nanotechnology Strategies to Overcome Limitations in Treatment of Challenging Diseases”, Biosciences Working Group (BSWG), The MITRE Corporation, January 23, 2013, McLean, VA.

20. “Nanotechnology-Based Targeted Cancer Treatment”, 2012 AAPS Annual Meeting, October 17, 2012, Chicago, IL.

21. “Combined Targeted Chemo and Gene Therapy for Tumor Suppression and Prevention of Metastasis”, Oligonucleotide Delivery: Biology, Engineering and Development, October 8, 2012, Hernstein, Austria.

22. “Boosting the EPR Effect by Targeting of Nanocarriers to Tumor-Specific Receptors”, Workshop “Critical Appraisal of EPR Effect and Intratumoral Distribution of Nanomedicine”, 38th Annual Meeting of the Controlled Release Society, July 14, 2012, Quebec City, Canada.

23. “Non-Viral Systemic Delivery of siRNA or Antisense Oligonucleotides Targeted to Jun N-Terminal Kinase 1 Prevents Cellular Hypoxic Damage”, 38th Annual Meeting of the Controlled Release Society, July 16, 2012, Quebec City, Canada.

24. “Nanotechnology Strategies to Overcome Multidrug Resistance”, School of Pharmacy, Oregon State University, April 19, 2012, Corvallis, OR.

25. “Cancer Stem Cells Specific Therapy: Targeted Nanomedicine for Simultaneous Suppression of CD44 Protein and Cell Death Induction”, 9^th International Conference and Workshop on Biological Barriers, March 6, 2012, Saarbrucken, Germany.

26. “Molecular Targeting of Drug Delivery Systems to Cancer”, Nanomedicine Research Center, Cedars-Sinai Medical Center, November 16, 2011, Los Angeles, CA.

27. “Nanotechnology Strategies to Overcome Limitations in Cancer Treatment”, Department of Pharmaceutical Sciences at the University at Buffalo, The State University of New York, October 6, 2011, Buffalo, NY.

28. “Combination of Tumor-Targeted Chemo- and Gene Therapy for Treatment of Primary Ovarian Cancer and Prevention of Metastases”, Ovarian Cancer Symposium: “One Force to Make a Difference”, June 18, 2011, Princeton, NJ.

29. “Multifunctional and Multicomponent Drug Delivery Systems for Cancer Treatment and Imaging”, The 2011 Annual Retreat on Cancer Research in New Jersey, May 26, 20011, Piscataway, NJ.

30. “Nanotechnology Strategies to Overcome Limitations in Drug Delivery: Opportunities and Challenges”, The Eighth International Nanomedicine and Drug Delivery Symposium, October 3, 2010, Omaha, NE.

31. “Molecular Targeting of Drug Delivery Systems to Cancer”, Gordon Research Conferences: Drug Carriers in Medicine and Biology, August 17, 2010, Waterville Valley, NH.

32. “Nanotechnology Strategies to Overcome Limitations in Cancer Treatment”, Particles 2010: Medical/Biochemical Diagnostic, Pharmaceutical, and Drug Delivery Applications of Particle Technology, May 23, 2010, Lake Buena Vista, FL.

33. “Nanotechnology Strategies to Overcome Limitations in Cancer Chemotherapy”, Department of Pharmaceutical Sciences, Wayne State University, April 28, 2010, Detroit, MI.

34. “Nanotechnology Strategies to Overcome Limitations in Drug Delivery: Opportunities and Challenges”, New York Society of Cosmetic Chemists (NYSCC) Spring Seminar, April 21, 2010, West Orange NJ.

35. “Nanotechnology Strategies to Overcome Limitations in Drug Delivery: Opportunities and Challenges”, Clinical Applications of Quantum Dot and Nanoparticle Technology, University of Illinois at Chicago Center for Clinical and Translational Science (CCTS), April 13, 2010, Chicago, IL.

36. “Mechanisms of Cellular Drug Resistance and Strategies to Overcome It”, Symposium on Biomedical Polymers for Drug Delivery, March 27, 2010, Salt Lake City, UT.

37. “Nanotechnology Strategies to Overcome Limitations in Drug Delivery: Opportunities and Challenges”, University of Wisconsin, March 17, 2010, Madison, WI.

38. “Nanotechnology Strategies to Overcome Limitations in Cancer Chemotherapy”, F. Hoffmann-La Roche Ltd, January 29, 2010, Nutley, NJ.

39. “New horizons in treatment of lung cancer: Combinatorial liposomal inhalation delivery of drugs and suppressors of cellular resistance”, Liposome advances: Recent trends and progress, December 13, 2009, London, UK.

40. “Targeted multifunctional nanocarriers for tumor treatment and imaging”, Annual Meeting of the American Association of Pharmaceutical Scientists, November 11, 2009, Los Angeles, CA.

41. “Inhalatory co-delivery of anticancer drugs and antisense oligonucleotides/siRNA for lung cancer treatment”, 35th Annual Meeting of the Controlled Release Society, July 22, 2009, Copenhagen, Denmark.

42. “Nanotechnology Strategies to Overcome Limitations in Drug Delivery: Opportunities and Challenges”, 41^st Annual Pharmaceutics Graduate Student Research Meeting “Globalization of the Pharmaceutical Industry”, June 26, 2009, Purdue University, West Lafayette, IN.

43. “Nanotechnology Strategies to Overcome Limitations in Drug Delivery: Opportunities and Challenges”, AAPS Workshop on Evolving Science and Technology in Physical Pharmacy and Biopharmaceutics, May 15, 2009, Baltimore, MD.

44. “Receptor Targeted Nanocarriers for Tumor-Specific Treatment and Imaging”, 14th International Symposium on Recent Advances in Drug Delivery Systems, February 18, 2009, Salt Lake City, UT.

45. “Multifunctional Nanotherapeutics for Cancer Treatment”, American Association for Cancer Research – American Chemical Society Joint Conference on: Chemistry in Cancer Research: A Vital Partnership in Drug Discovery and Development, February 10, 2009, New Orleans, LA.

46. “Receptor Targeted Nanocarriers for Tumor-Specific Treatment and Imaging”, The Provost Interdisciplinary Seminar Series on Targeted Therapeutics and Drug Delivery Systems, The University of Pennsylvania School of Medicine, Philadelphia, PA, January 14, 2009.

47. “Receptor-targeted nanocarriers for tumor-specific treatment and imaging”, Birck Nanotechnology Center, Purdue University, West Lafayette, IN, December 11, 2008.

48. “Efficient Co-Delivery of siRNA/Antisense Oligonucleotides and Drug for Lung Cancer Treatment”, 36^th Annual Scientific Session of the New Jersey Thoracic Society, New Brunswick, NJ, June 6, 2008.

49. “Nanocarriers for Tumor-Targeted Drug Delivery”, 2008 NSTI Nanotech 2008 11th Annual Meeting, NCI/NSTI Special Symposium on Nanotechnology for Cancer Prevention, Diagnosis and Treatment, Boston, MA, June 4, 2008.

50. “Targeted Multifunctional Nanocarriers for Tumor Treatment and Imaging”, Toward the Development of Drug Delivery Systems, 2^nd Annual Meeting of Italian Chapter of AAPS, Perugia, Italy, March 7, 2008.

51. “Targeted Multifunctional Nanocarriers for Intracellular Drug Delivery”, University of Ferrara, Italy, March 6, 2008.

52. “Targeted Multifunctional Nanocarriers for Tumor Treatment and Imaging”, School of Pharmacy, University of Rhode Island, Kingston, RI, May 15, 2008.

53. “Tumor – Targeted Anticancer Prodrugs”, Annual Meeting of the American Association of Pharmaceutical Scientists, San Diego, CA, November 15, 2007.

54. “Targeted Multicomponent Nanocarriers for Cancer Treatment and Diagnostics”, The Fifth International Nanomedicine and Drug Delivery Symposium, Boston, MA, November 2, 2007.

55. “Multifunctional Drug Delivery System for Inhalatory Treatment of Lung Cancer”, The Biennial New Jersey Pharmaceutical Conference of 2007, New Brunswick, NJ, October 5, 2007.

56. “Targeted Multifunctional Nanocarriers for Intracellular Drug Delivery”, Department of Pharmaceutics at the University of Minnesota, Minneapolis, MN, September 20, 2007.

57. “Targeted multicomponent nanocarriers in cancer treatment”, the 6th Annual Meeting of the Israeli Chapter of the Controlled Release Society on September 5, 2007, Cesaria, Israel.

58. “Targeted Multifunctional Drug Delivery Systems for Cancer Treatment and Imaging” Chemistry and Chemical Biology Department at Stevens Institute of Technology, Hoboken, NJ., September 12, 2007.

59. “Tumor-Specific Targeting of Drug Delivery Systems for Cancer Therapy and Imaging”, 34th Annual Meeting of the Controlled Release Society, Long Beach, CA, July 11, 2007.

60. “Complex Liposomal Drug Delivery System for Inhalatory Treatment of Lung Cancer”, 35th Annual Scientific Session of the New Jersey Thoracic Society, New Brunswick, NJ, June 1, 2007.

61. “Targeted Multifunctional Nanocarriers for Intracellular Drug Delivery”, Department of Chemistry, Newark, Rutgers, The State University of New Jersey, Newark, NJ, March 30, 2007.

62. “Receptor Targeting of Polymer Therapeutics and Imaging Agents to Tumor”, International Symposium on Polymer Therapeutics ISPT-07, Berlin, Germany, February 20, 2007.

63. “Tumor-Specific Targeting of Drug Delivery Systems”, Novartis Pharmaceuticals, East Hanover, NJ, November 17, 2006.

64. “Targeted Nanocarriers for Intracellular Drug Delivery”, Targeted Nanocarriers and Therapeutics, Institute for Translational Medicine and Therapeutics, The University of Pennsylvania School of Medicine, Philadelphia, PA, November 16, 2006.

65. “Tumor - Targeting Liposomal Complex for Short Interfering RNA Delivery”, Georgetown University Medical Center, Washington DC, October 24, 2006.

66. “Targeted Polymeric Prodrug with Multivalent Components for Cancer Therapy”, the 7th International Biorelated Polymers Symposium at the 232nd American Chemical Society Meeting, San Francisco, CA, September 12, 2006.

67. “Molecular targeting of drug delivery system to lung cancer”, 34^th Annual Scientific Session of New Jersey Thoracic Society, New Brunswick, NJ, June 2, 2006.

68. “Targeted Proapoptotic Drug Delivery System for Chemotherapy of Ovarian Cancer”, The Cancer Institute of New Jersey, New Brunswick, NJ, May 5, 2006.

69. “Extracellular and intracellular molecular targeting of drug delivery system to cancer”, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, March 31, 2006.

70. “Targeted anticancer polymeric prodrugs”, Abbott Laboratories, Abbott Park, IL, March 23, 2006.

71. “Complex drug delivery composition for treating cancer”, Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT, February 27, 2006.

72. “Advances in targeted drug delivery for cancer treatment”, Bristol-Myers Squibb Co., New Brunswick, NJ, February 3, 2006.

73. “Targeted drug delivery systems for cancer therapy”, Department of Biopharmaceutical Sciences, University of Illinois at Chicago, Chicago IL, January 11, 2006.

74. “Advanced targeted drug delivery systems for cancer therapy”, International Conference on Advances in Pharmaceutical Research and Technology, Mumbai, India, November 25-29, 2005.

75. “Novel approaches in anticancer drug delivery”, The Biennial New Jersey Pharmaceutical Conference of 2005 “Contribution of Women in the Pharmaceutical Sciences”, East Brunswick, NJ, October 6, 2005.

76. “Delivery system for remediation of cellular hypoxic damage”, Third International Nanomedicine and Drug Delivery Symposium, Baltimore, MD, September 26-27, 2005.

77. “Molecular targeting of drug delivery systems to cancer”, College of Pharmacy, Howard University, Washington, DC, November 4, 2004.

78. “Targeted delivery of anticancer drugs and peptides by polyethylene glycol conjugates”, 7th Symposium on Biomaterials Science, New Brunswick, NJ, October 21-22, 2004.

79. “Extracellular and intracellular molecular targeting of drug delivery system to cancer cells”, World Conference on Dosing of Antiinfectivnes – Dosing the Magic Bullets, Nurnberg, Germany, September 9-11, 2004.

80. “A novel multicomponent delivery system to enhance the efficacy of lung cancer therapy”, 32^nd Annual Scientific Section of the New Jersey Thoracic Society, New Brunswick, NJ, June 4, 2004.

81. “Targeted proapoptotic anticancer drug delivery system”, College of Pharmacy, University of Maryland, Baltimore, MD, March 3, 2004.

82. “Molecular targeting of drug delivery systems to cancer cells by peptides and antisense oligonucleotides”, College of Pharmacy, University of Kentucky, Lexington, KY, February 27, 2004.

83. “Molecular targeting of cellular resistance in cancer”, 8th World Congress on Advances in Oncology and 6th International Symposium on Molecular Medicine, Crete, Greece, October 16, 2003.

84. “Multicomponent drug delivery system for enhancing the efficacy of cancer chemotherapy”, Meeting of the New Jersey Center for Biomaterials, New Brunswick, NJ, September 17, 2003.

85. “Molecular targeting of drug delivery systems to cancer cells by peptides and antisense oligonucleotides”, Department of Biopharmaceutical Sciences, University of Illinois at Chicago, Chicago IL, April 2, 2003.

86. “Genetic adaptation to life at high altitude: Adaptation to chronic hypoxia, relevance to disease at sea level”, University of Lima, Lima, Peru, March 14, 2003.

87. “Advanced targeted drug delivery systems for cancer therapy”, Myriad Genetics, Inc., Salt Lake City, UT, March 4, 2003.

88. “Molecular targeting of drug delivery systems to cancer cells by peptides and antisense oligonucleotides”, EOHSI, Piscataway, NJ, February 6, 2003.

89. “Targeted proapoptotic drug delivery systems in cancer chemotherapy”, 7th World Congress on Advances in Oncology and 5th International Symposium on Molecular Medicine, Hersonissos, Crete, Greece, October 11, 2002.

90. “Targeted proapoptotic drug delivery systems in cancer chemotherapy”, Cancer Institute of New Jersey (Breast Cancer Research Program), New Brunswick, NJ, May 2002.

91. “Advanced drug delivery systems in cancer chemotherapy”, The Screening Technologies Branch of the Developmental Therapeutics Program in Drug Discovery and Development, National Cancer Institute, Frederick, MD, March 2002.

92. “Enhancing the efficacy of chemotherapeutic drugs by the suppression of antiapoptotic cellular defense”, 6^th International Symposium on Predictive Oncology and Intervention Strategies, Pasteur Institute, Paris, France, February 2002.

93. “Novel drug delivery systems for cancer therapy”, Salvona, Dayton, NJ, January 2002.

94. “Enhancing the efficacy of chemotherapeutic drugs by the suppression of antiapoptotic cellular defense”, GPCC Retreat, The Center for Advanced Biotechnology and Medicine, UMDNJ, Piscataway, NJ, December 2001.

95. “Advanced drug delivery systems in cancer chemotherapy”, VectraMed, Princeton, NJ, December 2001.

96. “Enhancing the efficacy of anticancer drugs using multicomponent advanced drug delivery system”, The Cancer Institute of New Jersey, New Brunswick, NJ, December 2001.

97. “Advanced drug delivery systems in cancer chemotherapy”, Pharmaceutics Conference 2001, East Brunswick, NJ, November 2001.

98. A polymer drug delivery system for cancer therapy, New Jersey Center for Biomaterials, Piscataway, NJ, June 1, 2001.

99. Antitumor activity and cell death signaling pathway of free and polymer-bound doxorubicin. The PH 890, Pharmacy Seminar (Pharmaceutics, Spring 2001), Philadelphia College of Pharmacy, University of the Science, Philadelphia, PA, April 27, 2001.

100. Mechanisms of anticancer action of HPMA copolymer-bound doxorubicin, ENZON, Inc., Piscataway, NJ, November 16, 2000.

101. Mechanism of anticancer action of HPMA copolymer-bound doxorubicin, 40^th Microsymposium "Polymers in Medicine", Czech Republic, July 2000, Special Lecture #4.

102. “Cell death signaling pathways and antitumor activity polymer-bound drugs”, Department of Pharmacology and Toxicology, School of Pharmacy, University of Utah, Salt Lake City, UT, November 1999.

103. “Adaptation to moderate stress increases the resistance to severe hypoxia”, International Symposium on High-Altitude Medicine, Matsumoto, Japan, September 1992.

104. “The criterion for the selection of hypoxic impacts for interval hypoxic training”, International Symposium on Interval Hypoxic Training: Efficiency and Mechanisms of Action, Kiev, Ukraine, September 1992.

105. “Oxygen supply-consumption ratio as the criterion of tissue hypoxia”, Hypoxia and Ischemia: Basic and Applied Aspects, Berlin, Germany, September 1991.

106. “Primary and secondary disturbances of acid-base homeostasis”, Acid-base and Thermal Homeostasis, Syktyvkar, Russia, February 1991.

107. “Influence of adaptation to high altitude hypoxia on the resistance of an organism to oxygen deficiency and stress”, Functional Reserves and Adaptation, Kiev, Ukraine, September 1990.

108. “Peculiarities of organism oxygen supply under bronchial asthma in mountains”, Usage of Mountain Climate to Treatment and Prophylaxis, Nalchik, Russia, April 1988.

109. “The conformity between oxygen mass transfer and its consumption during hypoxia of different genesis”, Regulation of Respiration and Gas Mass Transfer in the Organism, Leningrad, Russia, April 1985.

Oral (Podium) Presentations

1. “Straight to the Target: A Novel Polymeric Prodrug with Multivalent Components for Cancer Therapy”, 33^rd International Symposium on Controlled Release of Bioactive Materials, Vienna, Austria, July 22-26, 2006.

2. “Hypoxia Inducible Factor - Targeted Anticancer Prodrug”, 32^nd International Symposium on Controlled Release of Bioactive Materials, Miami, FL, June 18-22, 2005.

3. “Targeted proapoptotic anticancer drug delivery system”, 31^st International Symposium on Controlled Release of Bioactive Materials, Honolulu. HI, June 15, 2004.

4. “Novel Targeted Drug Delivery Systems Combining Anticancer Drug, Targeting Moiety and Suppressors of Multidrug Resistance and Antiapoptotic Cellular Defense”, CRS Winter Symposia & 11^th International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, UT, March 3-6, 2003.

5. “Molecular targeting of drug delivery systems for ovarian carcinoma therapy”, International Symposium on Tumor Targeted Delivery Systems (CRS & NIH), Bethesda, MD, September 24, 2002.

6. “Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense with liposomes containing doxorubicin and antisense oligonucleotides targeting MDR1 and BCL-2 mRNA”, 29^th Annual Meeting of the Controlled Release Society, Seoul, Korea, July 25, 2002.

7. “Delivery of synthetic BCL-2 homology 3 domain (BH3) peptide by fusion with the Antennapedia internalization sequence in combination with an antiapoptotic drug concurrently enhances apoptosis and inhibits antiapoptotic defenses in human ovarian carcinoma”, Gordon Research Conference: Drug Carriers in Medicine and Biology, Ventura, CA, February 2002.

8. “Role of caspases in cellular signal transduction pathways of apoptosis induced by free and HPMA copolymer-bound doxorubicin”, The 27^th International Symposium on Controlled Release of Bioactive Materials, Paris, France, July 2000.

9. “Cell death signaling pathways, toxicity and antitumor activity of free and polymer-bound doxorubicin”, Molecular Genetics in Toxicology, 17^th Annual Meeting of Mountain West Chapter of Society of Toxicology, Breckenridge, CO, September 1999.

10. “EPR effect, multidrug resistance and the efficacy of HPMA copolymer-bound adriamycin in solid tumors with high vascularization”, The 26th International Symposium on Controlled Release of Bioactive Materials, Boston, MA, June 1999.

11. “Peculiarities of apoptosis induction and cell metabolism in human ovarian carcinoma cell lines exposed to free and HPMA copolymer bound adriamycin”, The 25th International Symposium on Controlled Release of Bioactive Materials, Las Vegas, NV, June 1998.

12. “Mechanisms of the increase in the work load after preliminary adaptation to intermittent hypoxia and training”, III World Congress of ISAM , Tokyo, Japan, May 1993.

13. “Towards a new way to elevate the resistance against damaging environmental impacts”, 1^st American – Ukrainian Workshop “Health Care: Clinical and Basic Research", Kiev, Ukraine, June 1993.

14. “Hypoxic acid-base changes, lipid peroxidation and oxygen supply-consumption ratio”, 7^th International Hypoxia Symposium, Lake Louise, Canada, February 1991.

15. “Adaptation to high altitude limits tissue hypoxia and lipid peroxidation under severe acute environmental hypoxia”, International Congress of Mountain Medicine, Crans-Montana, Switzerland, April 1991.

16. “Interrelation of lipid peroxidation and tissue hypoxia under hypoxic states of different genesis”, Constituent Congress of International Society for Pathophysiology, Moscow, Russia, May 1991.

17. “Role of primary disturbances of blood buffer capacity in the compensation of metabolic acidosis”, Actual Problems of Pathology of Respiration, Kujbyshev, Russia, November 1989.

18. “Factors which determine resistance of blood active reaction under hypoxia”, Reactivity and Resistance: Fundamental and Applied Aspects, Kiev, Ukraine, May 1987.

19. “Respiration, circulation, blood acid-base balance and oxygen regimen of organism in women-arid zone lenders with iron deficit anemia under the influence of mountain climate”, Human Adaptation in Different Climatogeographic and Industrial Environment, Novosibirsk, Russia, June 1981.

20. “Peculiarities of blood buffering properties and acid base status in girls with secondary anemia”, Annual Meeting of Physiological Society: Special and Clinical Physiology of Hypoxic States, Kiev, Ukraine, November 1979.

Oral (Podium) Presentations of the Graduate Students, Postdoctoral Fellows and Researchers from Minko’s Lab since Joining Rutgers in 2000

1. “Inhalation Treatment of Lung Cancer: The Influence of Composition, Size and Shape of Nanocarriers on Their Lung Accumulation”, The 2015 Annual Retreat on Cancer Research in New Jersey, May 20, 2015, Piscataway, NJ (O. Garbuzenko, G. Mainelis, O. Taratula, T. Minko).

2. “Dendrimer-based multifunctional nanomedicine platforms for targeted delivery of siRNA”, 10^th International Nanomedicine and Drug Delivery (NanoDDS’12) Symposium, December 6-7, 2012, Atlantic City, NJ (O. Taratula, O. B. Garbizenko, P. Kirkpatrick, I. Pandya, R. Savla, V. P. Pozharov, H. He, T. Minko).

3. “Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary codelivery of anticancer drugs and siRNA”, 38th Annual Meeting of the Controlled Release Society, July 31-August 3, 2011, National Harbor, MD (O. Taratula, M. Shah, O. Garbuzenko, T. Minko).

4. “The influence of composition, size, and shape of nanocarriers on their accumulation and retention in lungs after pulmonary (or inhalatorial) delivery”, The 2011 Annual Retreat on Cancer Research in New Jersey, May 26, 2011, Piscataway, NJ (O. Garbuzenko, O. Taratula, T. Minko).

5. “Receptor-targeted surface-engineered PPI dendrimer for efficient intracellular and intratumoral siRNA delivery”, 37th Annual Meeting of the Controlled Release Society, July 10-14, 2010, Portland, OR (O. Taratula, O. B. Garbuzenko, P. Kirkpatrick, I. Pandya, R. Savla, V. P. Pozharov, H. He, T. Minko).

6. “Combinatorial inhalatory co-delivery of drug and antisense oligonucleotides for treatment of lung cancer”, 37th Annual Meeting of the Controlled Release Society, July 10-14, 2010, Portland, OR (O. Garbuzenko, M. Saad, K. Reuhl, G. Mainalis, T. Minko).

7. “Combinatorial local inhalatory treatment of lung cancer”, Innovations in Drug Delivery Technologies, The Biennial New Jersey Pharmaceutical Conference of 2009, November 20, 2009, Piscataway, NJ (O. Garbuzenko, M. Saad, V. P. Pozharov, K. R. Reuhl, G. Mainelis, T. Minko).

8. “Dendrimers as Potential siRNA Delivery Vehicles for Efficient Cancer Therapy”, Innovations in Drug Delivery Technologies, The Biennial New Jersey Pharmaceutical Conference of 2009, November 20, 2009, Piscataway, NJ (O. Taratula, O. Garbuzenko, T. Minko).

9. “Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most effective for tumor specific treatment and imaging?” in 35th Annual Meeting of the Controlled Release Society, July 12-16, 2008, New York, NY (M. Saad, O. B. Garbuzenko, E. Ber, P. Chandna, J. J. Khandare, V. P. Pozharov, T. Minko).

10. “A novel targeted proapoptotic drug delivery system for efficient anticancer therapy” in 35th Annual Meeting of the Controlled Release Society, July 12-16, 2008, New York, NY (P. Chandna, M. Saad, Y. Wang, E. Ber, J. Khandare, A. A. Vetcher, V. A. Soldatenkov, T. Minko).

11. “JNK1 as a molecular target to limit cellular damage under hypoxia” in 35th Annual Meeting of the Controlled Release Society, July 12-16, 2008, New York, NY (S. Betigeri, O. B. Garbuzenko, T. Minko).

12. “Noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research” in The Annual Retreat on Cancer Research in New Jersey, May 28, 2008, Piscataway, NJ (M. Saad, O. B. Garbuzenko, J. J. Khandare, Y.Wang, A. A. Vetcher, V. A. Soldatenkov, T. Minko).

13. “Toward in vivo targeted delivery of siRNA for efficient cancer therapy” at The Annual Retreat on Cancer Research in New Jersey, , May 28, 2008, Piscataway, NJ (O. Taratula, R.Salva, I. Pandya, H. Geng, A. Wang, T. Minko, H. He).

14. “Targeted nanocarier-based delivery of near-infrared cyanine dye enhances tumor imaging” in the Fourth Nanomedicine and Drug Delivery Symposium, October 10, 2006, Omaha, NE (M. Saad, J. J. Khandare, Y. Wang, T. Minko).

15. “JNK1 as a molecular target to decrease cellular mortality under hypoxia”, 25th Annual Meeting of the Graduate Research Association of Students in Pharmacy (GRASP), June 10-12, 2005, New York, NY (S. Betigeri, R. I. Pakunlu, T. Minko).

16. “Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: Novel multicomponent delivery system”, 24th Annual Meeting of the Graduate Research Association of Students in Pharmacy (GRASP), June 4-6, 2004, Atlanta, GA (R. I. Pakunlu, Y. Wang, T. Minko).

17. “Potential use of the combined liposomal hypoxia inducible factor 1 alpha antisense oligonucleotides and doxorubicin as a novel anticancer therapy”, 24th Annual Meeting of the Graduate Research Association of Students in Pharmacy (GRASP), June 4-6, 2004, Atlanta, GA (Y. Wang, R. I. Pakunlu, T. Minko).

18. “Molecular targeting of drug delivery systems to cancer cells by BH3 and LHRH peptides”, 23rd Annual Meeting of the Graduate Research Association of Students in Pharmacy (GRASP), May 30 - June 1, 2003, Richmond, VA (S. S. Dharap, B. Qiu, S. Stein, P. J. Sinko, T. Minko).

Poster Presentations of the Graduate Students, Postdoctoral Fellows and Researchers from Minko’s Lab since Joining Rutgers in 2000 – Total: 124.